Product category:
Genomics
News Release from: Scienion | Subject: Antibody chips
Edited by the Laboratorytalk Editorial
Team on 09 September 2004
Antibody chips for research and
diagnostics
Chips will allow the simultaneous identification of many hundred medically relevant proteins from complex biological substrates
In a joint project with the Max-Planck-Institute for Molecular Genetics, Scienion is adapting its chip technology for protein applications Previously, the technology has mainly been used for nucleic acids chips
This article was originally published on Laboratorytalk on 26 Nov 2004 at 8.00am (UK)
Related stories
Dispensing of tiny liquid volumes
Instrument allows the aspiration of ultra low level liquid volumes within the picoliter to nanoliter range from different reservoirs and contact-free delivery
Integrated system for protein microarrays
Protocol and buffer specially designed for use with the HTA slides allows the efficient production and analysis of protein microarrays and is compatible with existing HTA platforms
The project aims to develop antibody chips for the analysis of human proteins and is funded by the Zukunftsfonds of Berlin.
Besides the adaptation of Scienion's 2D/3D chip technology for the detection of proteins and the development of appropriate bioinformatic solutions the characterisation and quality control of antibody libraries is an integral part of the project.
Modern techniques of mass spectrometry are applied.
Further reading
Ultra sensitive protein measurements for Maldi
Dispensing system technology is applicable for a variety of instruments and matrix assisted laser desorption ionisation (Maldi) mass spectrometry targets
Cell dispensing for miniaturised cell-based assays
Ultra low level liquid handling system allows the aspiration and dispensing of single cells or low amount of cells for a variety of cell-based assays in functional genomics and drug development
Initially, antibodies against 384 human proteins will be tested.
While the team at the Max-Planck-Institute for Molecular Genetics mainly focuses on the characterisation of the antibodies, Scienion works on the technological development of the chips.
The crucial step is an efficient and reproducible procedure for docking the antibodies to the chip surface without destroying their binding specificity.
The immobilisation process must also allow a sterically unhindered binding of the antigens.
Two techniques are used for the detection of the binding proteins (antigens): probes are supplied with a fluorescence dye and analysed with a fluorescence spectrometer.
Additionally, the mass spectrum of the binding proteins is detected by Maldi-Tof-MS in a high throughput manner.
Furthermore, scientists at Scienion will develop controls essential for data analysis and then integrate these controls into the chip layout and establish an efficient quality control.
Holger Eickhoff, CEO of Scienion, explained the advantages for customers: "These antibody chips will allow the simultaneous identification of many hundred medically relevant proteins from complex biological substrates: fast, cost effective, and with a high sensitivity".
In addition, Scienion will also offer the development of customised antibody chips.
Applications in diagnostics and drug development There is already a demand for this technological innovation for diagnostic applications.
At present Scienion's novel chip technology is used at the Max Delbruck Center for Molecular Medicine in a project of the German National Genome Research Net (NGFN).
Project coordinator Erich Wanker uses the Scienion know-how and the new antibody chips for the detection and characterisation of neuronal proteins: "Antibody chips provide us with new opportunities for a fast and parallel analysis of protein-protein interactions of neurodegenerative diseases like Alzheimer's disease, Parkinson or Huntington's chorea. Request a free brochure from Scienion ...
"The results of these studies contribute to a better understanding of molecular processes in the course of the diseases and hopefully will lead to the identification of new targets for innovative drugs.".
• Scienion: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
